Product Program year 2025 Source: CMS Open Payments

Mozobil

Drug Oncology

NDC 0024-5862-01

Open in the dashboard

General payments

$527,608

660 payments

Research payments

$24,575,444

63 payments

Through program year 2025, $527,608 in general payments and $24,575,444 in research payments were reported against Mozobil (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $342 4
2025 Research $90,000 2
2024 General $1,398 16
2024 Research $30,000 1
2023 General $4,470 59
2023 Research $148,170 3
2022 General $101,661 137
2022 Research $8,978,092 5
2021 General $88,347 138
2021 Research $5,211,432 12
2020 General $57,201 69
2020 Research $5,445,503 20
2019 General $274,190 237
2019 Research $4,672,246 20

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $279,345 313 payments
  2. Sanofi-Aventis U.S. LLC $248,263 347 payments
Top recipients General payments · program year 2025
  1. Dennis Lyu Pulmonary Disease · Ann Arbor, MI $92 27% · 1 payment
  2. Michael Combs Pulmonary Disease · Ann Arbor, MI $92 27% · 1 payment
  3. Joel Lopez-Figueroa Hematology & Oncology · Humacao, PR $83 24% · 1 payment
  4. Alexis Cruz Chacon Hematology & Oncology · San Juan, PR $75 22% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $184 54% · 2 practitioners
  2. Hematology & Oncology Internal Medicine $158 46% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Puerto Rico $158 46% · 2 recipients
  2. Michigan $92 27% · 1 recipient
  3. Tennessee $92 27% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to MOZOBIL
Billing code Providers Services Paid by Medicare
Injection, plerixafor, 1 mg J2562 2 1,108 $17,864

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

660 general · 63 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record